Value creation starts with a simple equation:
Our portfolio includes investments across all emerging disciplines, such as autonomous systems/AI, quantum technology, mobility, sustainable energy, genomics, synthetic biology, life sciences, and blockchain. This leads to a diversified portfolio of companies with category-creating potential.

Port Therapeutics
Professor Mikhail Shapiro. Ultrasound-enabled drug discovery.
Currently in stealth

DNATwo
Professor J. Campbell & B. Stoltz. Novel cancer therapeutics targeting DNA repair and replication.
Currently in stealth

HEPT
Professor Ali Hajimiri. Hybrid electronic, photonic technology.
Currently in stealth

Flion
Professor Kimberly See. Sustainable energy storage from abundant eco-materials.
Currently in stealth

Tera AI
Tony Zhang, PhD. Superhuman reasoning of the physical world.
Currently in stealth

Receptive Bio
Professor Viviana Gradinaru. Neuroscience target discovery.
Currently in stealth

Palamedrix
Acquired by Somalogic (NASDAQ: SLGC). Intra-cellular interrogation at analyte resolution.

Asymptote Bio
Professor Michael Elowitz. Synthetic Biology inspired therapeutics.
Currently in stealth

Switch Therapeutics
Professor Bill Goddard. Next-generation RNAi therapies for unmet diseases.